152 related articles for article (PubMed ID: 29948972)
1. Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma.
Deng LL; Deng HB; Lu CL; Gao G; Wang F; Yang Y
Clin Transl Oncol; 2019 Feb; 21(2):197-205. PubMed ID: 29948972
[TBL] [Abstract][Full Text] [Related]
2. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
[TBL] [Abstract][Full Text] [Related]
3. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
5. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.
Cao Y; Zhang G; Wang P; Zhou J; Gan W; Song Y; Huang L; Zhang Y; Luo G; Gong J; Zhang L
BMC Gastroenterol; 2017 Jan; 17(1):2. PubMed ID: 28056823
[TBL] [Abstract][Full Text] [Related]
7. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
Han Y; Wang XB; Xiao N; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
[TBL] [Abstract][Full Text] [Related]
8. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
9. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
[TBL] [Abstract][Full Text] [Related]
10. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer.
Quéré G; Descourt R; Robinet G; Autret S; Raguenes O; Fercot B; Alemany P; Uguen A; Férec C; Quintin-Roué I; Le Gac G
BMC Cancer; 2016 Mar; 16():210. PubMed ID: 26968843
[TBL] [Abstract][Full Text] [Related]
11. Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
Han Y; Yu DP; Zhou SJ; Song XY; Li YS; Xiao N; Liu ZD; Sun XJ; Zhao QY; Liu SK
Genet Mol Res; 2014 Oct; 13(4):8913-24. PubMed ID: 25366782
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients.
Yu D; Li J; Han Y; Liu S; Xiao N; Li Y; Sun X; Liu Z
Chin Med J (Engl); 2014; 127(8):1464-8. PubMed ID: 24762590
[TBL] [Abstract][Full Text] [Related]
13. Association of metastatic pattern and molecular status in stage IV non-small cell lung cancer adenocarcinoma.
Dormieux A; Mezquita L; Cournede PH; Remon J; Tazdait M; Lacroix L; Rouleau E; Adam J; Bluthgen MV; Facchinetti F; Tselikas L; Aboubakar F; Naltet C; Lavaud P; Gazzah A; Le Pechoux C; Lassau N; Balleyguier C; Planchard D; Besse B; Caramella C
Eur Radiol; 2020 Sep; 30(9):5021-5028. PubMed ID: 32323012
[TBL] [Abstract][Full Text] [Related]
14. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics.
Li J; Sun P; Huang T; He S; Li L; Xue G
Medicine (Baltimore); 2021 Apr; 100(14):e25344. PubMed ID: 33832110
[TBL] [Abstract][Full Text] [Related]
15. Histopathological and molecular profiling of lung adenocarcinoma skin metastases reveals specific features.
Forest F; Laville D; Habougit C; Da Cruz V; Casteillo F; Yvorel V; Bard-Sorel S; Godard W; Picot T; Tiffet O; Perrot JL; Péoc'h M
Histopathology; 2021 Dec; 79(6):1051-1060. PubMed ID: 34313338
[TBL] [Abstract][Full Text] [Related]
16. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
17. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
[TBL] [Abstract][Full Text] [Related]
18. Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing.
Li D; Huang Y; Cai L; Wu M; Bao H; Xu Y; Wei Y; Wu S; Wu X; Shao Y; Zhao W; Lv G; Huang S; Zhang T; Shi Y
Neoplasia; 2021 Dec; 23(12):1204-1212. PubMed ID: 34735995
[TBL] [Abstract][Full Text] [Related]
19. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
[TBL] [Abstract][Full Text] [Related]
20. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
